181 related articles for article (PubMed ID: 28265739)
1. Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.
Finkle JH; Jo SY; Ferguson MK; Liu HY; Zhang C; Zhu X; Yuan C; Pu Y
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1275-1284. PubMed ID: 28265739
[TBL] [Abstract][Full Text] [Related]
2. An updated and validated PET/CT volumetric prognostic index for non-small cell lung cancer.
Finkle JH; Penney BC; Pu Y
Lung Cancer; 2018 Sep; 123():136-141. PubMed ID: 30089584
[TBL] [Abstract][Full Text] [Related]
3. Metabolic active tumour volume quantified on [
Rocha ALG; da Conceição MAM; da Cunha Sequeira Mano FXP; Martins HC; Costa GMLM; Dos Santos Oliveiros Paiva BCB; Lapa PAA
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3601-3611. PubMed ID: 34570257
[TBL] [Abstract][Full Text] [Related]
4. Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging.
Pu Y; Zhang JX; Liu H; Appelbaum D; Meng J; Penney BC
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2079-2092. PubMed ID: 29882161
[TBL] [Abstract][Full Text] [Related]
5. A new PET/CT volumetric prognostic index for non-small cell lung cancer.
Zhang H; Wroblewski K; Jiang Y; Penney BC; Appelbaum D; Simon CA; Salgia R; Pu Y
Lung Cancer; 2015 Jul; 89(1):43-9. PubMed ID: 25936471
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of quantitative PET/CT in patients with a nonsmall cell lung cancer and another primary cancer.
Zhu X; Liao C; Penney BC; Li F; Ferguson MK; Simon CA; Wu T; Liu H; Pu Y
Nucl Med Commun; 2017 Feb; 38(2):185-192. PubMed ID: 27922540
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
9. FDG PET/CT Tumor Dissemination Characteristic Predicts the Outcome of First-Line Systemic Therapy in Non-small Cell Lung Cancer.
Tan W; Zhang Y; Wang J; Zheng Z; Xing L; Sun X
Acad Radiol; 2023 Dec; 30(12):2904-2912. PubMed ID: 37202226
[TBL] [Abstract][Full Text] [Related]
10. Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images.
Zhang C; Liao C; Penney BC; Appelbaum DE; Simon CA; Pu Y
Radiology; 2015 Jun; 275(3):862-9. PubMed ID: 25584710
[TBL] [Abstract][Full Text] [Related]
11. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of thoracic tumor staging and volume parameters in non-small cell lung cancer patients with synchronous solitary bone metastasis.
Deng K; Li S; Zhang J; Ye X; Yao K; Li Y; Xiao J
J Thorac Dis; 2022 Apr; 14(4):1130-1138. PubMed ID: 35572912
[TBL] [Abstract][Full Text] [Related]
13. Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.
Zhang H; Wroblewski K; Appelbaum D; Pu Y
Int J Comput Assist Radiol Surg; 2013 Mar; 8(2):181-91. PubMed ID: 22644386
[TBL] [Abstract][Full Text] [Related]
14. Whole body metabolic tumor volume is a prognostic marker in patients with newly diagnosed stage 3B non-small cell lung cancer, confirmed with external validation.
Dashevsky BZ; Zhang C; Yan L; Yuan C; Xiong L; Liu Y; Liu H; Kong FS; Pu Y
Eur J Hybrid Imaging; 2017; 1(1):8. PubMed ID: 29782599
[TBL] [Abstract][Full Text] [Related]
15. Metabolic tumor burden quantified on [
Lapa P; Oliveiros B; Marques M; Isidoro J; Alves FC; Costa JMN; Costa G; de Lima JP
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2169-2178. PubMed ID: 28785842
[TBL] [Abstract][Full Text] [Related]
16. Developing a clinical and PET/CT volumetric prognostic index for risk assessment and management of NSCLC patients after initial therapy.
Liu L; Zhang J; Ferguson MK; Appelbaum D; Zhang JX; Pu Y
Front Biosci (Landmark Ed); 2022 Jan; 27(1):16. PubMed ID: 35090321
[TBL] [Abstract][Full Text] [Related]
17. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
[TBL] [Abstract][Full Text] [Related]
18. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
19. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
Agarwal M; Brahmanday G; Bajaj SK; Ravikrishnan KP; Wong CY
Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):691-8. PubMed ID: 19915840
[TBL] [Abstract][Full Text] [Related]
20. Metabolic tumor volume derived from
Ding C; Mao X; Li N; Huang M; Huang Z; Bao W; Li H; Fan J
Hell J Nucl Med; 2022; 25(1):63-70. PubMed ID: 35503557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]